← Leaderboards
Gangadhara R Sareddy
University Of Texas Hlth Science Center
$1,601,264
Attributed
$1,601,264
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $360.4K · FY2019–23$500K$375K$250K$125K$0
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$1,601,264 · 1
By mechanism
R01$1,601,264 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Texas Hlth Science Center
Same institution · by research overlap
- Ricardo C Aguiar$4,897,608
- Geethanjali Vipulanandan$202,777
- Yves Claude Gorin$1,843,830
- Andrew Jacob Brenner$6,506,512
- Stanton Furst McHardy$2,435,808
Others in their field
Other Emerging Leaders on “External Beam Radiation Therapy”
- Zachary Scott Morris · University Of Wisconsin-Madison$7,253,526
- Joseph Grudzinski · Voximetry, Inc.$4,969,457
- Noah M Hahn · Johns Hopkins University$3,167,009
- Michael Ghaly · Radiopharmaceutical Imaging And Dosimetry, Llc$3,135,910
- Paul Wickre · Voximetry, Inc.$3,126,083
- Peter S Laviolette · Medical College Of Wisconsin$2,965,890
Research focus
External Beam Radiation TherapyGene ExpressionAffectEpigenetic TherapyAngiogenesisExcisionBiochemicalApoptosisCellsAttenuatedCell TherapyChemotherapeutic AgentBindingAdjuvant ChemotherapyChip-SeqClinically SignificantCombined Modality TherapyCrispr/Cas TechnologyEfficacy TestingEndoplasmic Reticulum StressEnvironmentEnzymesEpigenetic ProcessGenes
Grant awards (6)
KDM1A inhibitors as novel therapeutics for glioblastoma$293,563
R01 · FY2023 · NS · contact PI
KDM1A inhibitors as novel therapeutics for glioblastoma$293,563
R01 · FY2022 · NS · contact PI
KDM1A inhibitors as novel therapeutics for glioblastoma$360,380
R01 · FY2021 · NS · contact PI
KDM1A inhibitors as novel therapeutics for glioblastoma$293,563
R01 · FY2020 · NS · contact PI
KDM1A inhibitors as novel therapeutics for glioblastoma$66,632
R01 · FY2020 · NS · contact PI
KDM1A inhibitors as novel therapeutics for glioblastoma$293,563
R01 · FY2019 · NS · contact PI